{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"25.8"},{"groupId":"OG001","value":"47.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"151"},{"groupId":"OG001","value":"151"}],"units":"Participants"}],"description":"Percentage of participants having at least one Hb value greater than (\\>) 12 g/dL during the first 8 weeks of the study was reported.","groups":[{"description":"Participants received Mircera (Methoxy polyethylene glycol-epoetin beta), administered SC at a starting dose of 1.2 mcg/kg once every 4 weeks for 28 weeks.","id":"OG000","title":"Mircera"},{"description":"Participants received darbepoetin alfa, administered SC once weekly or once every 2 weeks according to local labeling specifications for 28 weeks.","id":"OG001","title":"Darbepoetin Alfa"}],"paramType":"NUMBER","populationDescription":"ITT population. Here, N=number of participants evaluable for this measure.","reportingStatus":"POSTED","timeFrame":"Baseline to Week 8","title":"Percentage of Participants Who Had at Least 1 Hemoglobin Value Exceeding 12.0 g/dL","type":"SECONDARY","unitOfMeasure":"percentage of participants"}